This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
stored at -80F• Chemiluminescent automated immunoassay using MPO-
specific monoclonal antibodies in a 2-step sandwich format• Dynamic range of 0–10,000 pmol/L• Limit of detection <20.0 pmol/L• Functional sensitivity of < 50.0 pmol/L• Total CV 20%
Correlation Analyses• Weak correlation between MPO and hsCRP (r = 0.186;
p<0.0001)
Novel Statistical Analyses• Area under ROC curve (AUC) was 67%• Integrated discrimination improvement (IDI) of 10% (p<0.001)• Event-specific net reclassification (NRI) of 6% (p=0.022)
Conclusions1. Plasma MPO concentration provide independent prognostic value
for the prediction of long-term incident major adverse cardiovascular events in a stable, medically managed patient population with coronary artery disease.
2. In individuals with increased hsCRP concentrations, we observed lower risk of incident MACEs when concomitant MPO concentrations were lower versus when MPO concentrations were higher.
• Different biomarkers may provide distinctive insights into underlying pathophysiology.
• Identification of intermediate risk patients may provide useful clinical insights into individual disease states.
• Clinical significance of a specific biomarker requires appropriate clinical interpretation of patient populations being studied, with the support of rigorous statistical justification.
• Standard statistical analyses techniques provide quantification of incremental risk, but are difficult to apply in clinical setting.